JP2021534195A5 - - Google Patents

Info

Publication number
JP2021534195A5
JP2021534195A5 JP2021509764A JP2021509764A JP2021534195A5 JP 2021534195 A5 JP2021534195 A5 JP 2021534195A5 JP 2021509764 A JP2021509764 A JP 2021509764A JP 2021509764 A JP2021509764 A JP 2021509764A JP 2021534195 A5 JP2021534195 A5 JP 2021534195A5
Authority
JP
Japan
Prior art keywords
hmga2
formulation
tgfβ
expression
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509764A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534195A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047734 external-priority patent/WO2020041607A1/en
Publication of JP2021534195A publication Critical patent/JP2021534195A/ja
Publication of JP2021534195A5 publication Critical patent/JP2021534195A5/ja
Pending legal-status Critical Current

Links

JP2021509764A 2018-08-22 2019-08-22 標的TGF−β阻害によるトリプルネガティブ乳がんの処置 Pending JP2021534195A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721249P 2018-08-22 2018-08-22
US62/721,249 2018-08-22
PCT/US2019/047734 WO2020041607A1 (en) 2018-08-22 2019-08-22 Treatment of triple negative breast cancer with targeted tgf-b inhibition

Publications (2)

Publication Number Publication Date
JP2021534195A JP2021534195A (ja) 2021-12-09
JP2021534195A5 true JP2021534195A5 (cg-RX-API-DMAC7.html) 2022-08-29

Family

ID=69591342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509764A Pending JP2021534195A (ja) 2018-08-22 2019-08-22 標的TGF−β阻害によるトリプルネガティブ乳がんの処置

Country Status (12)

Country Link
US (1) US20210196822A1 (cg-RX-API-DMAC7.html)
EP (1) EP3840776A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021534195A (cg-RX-API-DMAC7.html)
KR (1) KR20210046716A (cg-RX-API-DMAC7.html)
CN (1) CN113271962A (cg-RX-API-DMAC7.html)
AU (1) AU2019325593A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003093A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110276A1 (cg-RX-API-DMAC7.html)
IL (1) IL280958A (cg-RX-API-DMAC7.html)
MX (1) MX2021002006A (cg-RX-API-DMAC7.html)
SG (1) SG11202101663WA (cg-RX-API-DMAC7.html)
WO (1) WO2020041607A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4194002A4 (en) * 2020-07-24 2024-08-14 Mabwell (Shanghai) Bioscience Co., Ltd. TGF-BETA RII MUTANT AND ASSOCIATED FUSION PROTEIN
CN121319180A (zh) * 2020-07-28 2026-01-13 乐普生物科技股份有限公司 靶向PD-L1和TGF-β的双功能分子
CN112640887B (zh) * 2020-12-25 2022-05-13 武汉睿健医药科技有限公司 一种神经干细胞冻存液及其应用
KR20230020041A (ko) 2021-08-02 2023-02-10 숙명여자대학교산학협력단 miR-181a 억제제 및 커큐민을 유효성분으로 포함하는 삼중음성유방암 치료용 조성물
JP7734856B2 (ja) * 2021-09-30 2025-09-05 ▲貝▼▲達▼▲薬▼▲業▼股▲フン▼有限公司 二重特異性抗体及びその使用
CN115671314A (zh) * 2022-11-16 2023-02-03 中南大学 一种抗血管生成靶向黑磷纳米片的制备方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4503617B2 (ja) * 2003-12-23 2010-07-14 ライナット ニューロサイエンス コーポレイション アゴニスト抗trkC抗体および該抗体を用いる方法
JP2016524150A (ja) * 2013-06-19 2016-08-12 ユニヴァーシティー オブ マイアミUniversity of Miami 乳癌の分類、予測及び処置のための分類システム、方法及びキット
HRP20210977T1 (hr) * 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
US20180104232A1 (en) * 2015-03-12 2018-04-19 The University Of Chicago Methods for determining prognosis for breast cancer patients
HK1259409A1 (zh) * 2015-10-13 2019-11-29 The Scripps Research Institute 酪蛋白激酶1δ在乳腺癌中的治疗靶向

Similar Documents

Publication Publication Date Title
Hamid et al. Intratumoral immunotherapy—update 2019
US20240390489A1 (en) Methods of increasing strength and functionality with gdf8 inhibitors
JP6837105B2 (ja) Il−4r阻害剤の投与による好酸球性食道炎を治療する方法
CN112546217B (zh) 用于治疗肿瘤的抗b7-h1抗体
JP6607850B2 (ja) Vegfアンタゴニスト及び抗ctla−4抗体の組み合わせを含む方法及び組成物
RU2622021C2 (ru) Лечение кахексии
US20220273722A1 (en) Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment
CN109789196A (zh) 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
KR101910760B1 (ko) 종양성 질병들에 대한 치료
Shen et al. Baicalin is curative against rotavirus damp heat diarrhea by tuning colonic mucosal barrier and lung immune function
CN110179989A (zh) 治疗狼疮的方法和组合物
KR20220093349A (ko) 흑색종에 대한 lag-3 길항제 요법
TWI924623B (zh) 頭頸癌之治療
KR20210046716A (ko) 표적화된 TGF-β 억제에 의한 삼중 음성 유방암의 치료
CN102395602B (zh) 在疾病治疗方法中使用的b‑淋巴细胞靶向剂
JP2021523096A5 (cg-RX-API-DMAC7.html)
KR20230121995A (ko) 톨-유사 수용체 작용제를 사용한 암 요법
CN121622884A (zh) 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
WO2021221668A1 (en) Anti-sars-cov-2 monoclonal antibody compositions
RU2021107205A (ru) ЛЕЧЕНИЕ ТРОЙНОГО НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ ПУТЕМ НАПРАВЛЕННОГО ИНГИБИРОВАНИЯ TGF-β
CN117083073A (zh) 用于治疗t细胞和b细胞介导的障碍以及t细胞和b细胞癌症的抗cd6抗体缀合物
JP2003522774A (ja) 異種型抗体療法の効力の診断のための方法
CN115734971A (zh) 抗ang-2抗体及其用途
CN114081945A (zh) 一种治疗肿瘤疾病的联合用药组合物及应用
CN120248122A (zh) 一种靶向uPAR的单链抗体、嵌合抗原受体及其应用